Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

Biotechnology

Healthcare
$7.22 -2.70%

-$0.26 today

Market cap
$632.52M
Beta
2.00
P/E (TTM)
-5.1
EPS (TTM)
-$1.80
52W Low $4.02High $36.26

Volume 1.27M

Average 1.27M

Returns on capital

Olema Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-33.9%

avg -14.1%

ROIC

-37.0%

avg 10.2%

ROA

-30.5%

avg -438.7%

Analysis

ROA is currently the strongest return metric at -30.5% versus its period average of -438.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Sean Bohen

President, Chief Executive Officer & DirectorUSD 1.18M59275.00K0.31%

Naseem Zojwalla

Chief Medical OfficerUSD 777.97K53106.25K0.12%

Shawnte Mitchell

Chief Legal Officer & Corporate SecretaryUSD 664.75K480<0.01%

David C. Myles

Chief Scientific OfficerUSD 200K63106.25K0.12%

Jason O'Byrne

CFO, Principal Financial Officer & Accounting Officer—57650.00K0.74%

Julie Dexter

Senior Vice President & Head of People————

Kamesh Kuchimanchi

Senior Vice President of Regulatory Affairs & Quality Assurance————

Mark Shilkrut

Senior Vice President of Clinical Development————

Richard Hernandez

Senior Vice President of Clinical Development Operations————

Courtney O'Konek

Vice President of Corporate Communications————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

25

$24.74M

Net Transaction Value

−$24.74M

Net selling

Most Active

Myles David C.

8 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 24, 26

Harmon Cyrus

Direct

Sell$146.4K
Jul 23, 26

Harmon Cyrus

Direct

Sell$144.7K
Mar 4, 26

Mitchell Shawnte

Direct

Sell$600.6K
Mar 4, 26

Mitchell Shawnte

Direct

Sell$5.8K
Mar 3, 26

Mitchell Shawnte

Direct

Sell$345.2K
Jan 20, 26

Harmon Cyrus

Direct

Sell$268.8K
Jan 15, 26

Kovacs Shane William Charles

Direct

Sell$2.9M
Jan 14, 26

Myles David C.

Direct

Sell$428.9K
Jan 14, 26

Myles David C.

Direct

Sell$1M
Jan 14, 26

Harmon Cyrus

Direct

Sell$101.6K

1–10 of 25

Summary

Insiders reported 0 buys worth $0.00 and 25 sells worth $24.74M over the last 12 months. That adds up to net selling of $24.74M. Myles David C. was the most active insider with 8 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Olema Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Competitors

Peer companies in the same sector

Health

Questions

Management questions

Common questions about OLMA's management, answered from reported figures.

Who manages OLMA?

Olema Pharmaceuticals, Inc. (OLMA) lists 10 active executives. The top listed executive is Sean Bohen, President, Chief Executive Officer & Director.

Are OLMA insiders buying or selling?

Recent insider activity shows net buying of $7.38M.